THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFUNCTION
The present invention provides a therapeutic and/or prophylactic agent for, for example, frontal lobe dysfunction (for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease, cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy, frontotemporal dementia and the like) and the like), Lewy body disease (for example, cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) and the like, which contains a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
1 - 19 . (canceled)
20 . A method for the treatment and/or prophylaxis of frontal lobe dysfunction, comprising a step of administering an effective amount of a compound represented by the formula (I):
or a pharmaceutically acceptable salt thereof.
21 . The method according to claim 20 , wherein the frontal lobe dysfunction is cognitive impairment.
22 . The method according to claim 21 , wherein the cognitive impairment is cognitive impairment in Parkinson's disease, cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy or frontotemporal dementia.
23 . The method according to claim 21 , wherein the cognitive impairment is cognitive impairment in Parkinson's disease.
24 . The method according to claim 23 , wherein the cognitive impairment in Parkinson's disease is executive dysfunction, memory disorder, impairment in visual spatial cognition or smell disturbance.
25 . The method according to claim 21 , wherein the cognitive impairment is cognitive impairment caused by chronic stress.
26 . The method according to claim 21 , wherein the cognitive impairment is dementia with lewy bodies.
27 . The method according to claim 20 , wherein the frontal lobe dysfunction is cognitive impairment due to a decline in dopamine function in the medial prefrontal cortex.
28 . A method for the treatment and/or prophylaxis of Lewy body disease, comprising a step of administering an effective amount of a compound represented by the formula (I):
or a pharmaceutically acceptable salt thereof.
29 . The method according to claim 28 , wherein the Lewy body disease is cognitive impairment in Parkinson's disease.
30 . The method according to claim 28 , wherein the Lewy body disease is diffuse Lewy body disease.
31 . The method according to claim 28 , wherein the Lewy body disease is dementia with lewy bodies.
32 . The method according to claim 28 , wherein the Lewy body disease is movement disorder associated with Lewy body disease.